文献速递冠心病外科

冠状动脉旁路移植合并外科消融治疗房颤的1年死亡率和费用

One-year mortality and costs associated with surgical ablation for atrial fibrillation concomitant to coronary artery bypass grafting.
PubMed 文献 · Eur J Cardiothorac Surg · 2017-01-01

该研究基于2013年美国Medicare数据库3745例既往房颤接受CABG的患者,比较合并外科消融(SA)与未消融者的风险调整后结局和费用。SA组90天后生存显著更优(HR=0.58,P=0.03),但起搏器/ICD植入率和费用更高。

要点

  • 合并SA未增加手术死亡率和围术期卒中风险
  • SA组90天后风险调整生存显著优于非SA组(HR=0.58,P=0.03)
  • SA组1年心血管植入式电子装置植入率更高(HR=1.20,P=0.01)

核心结论

  • 在既往房颤的CABG患者中,合并SA不增加手术死亡和卒中风险,但增加费用和1年电子装置植入率。
  • 接受SA的患者风险调整后晚期生存显著改善。

研究设计与样本

  • 回顾性队列研究,纳入2013年美国Medicare数据库中3745例既往房颤且接受CABG的受益人。
  • 分为合并SA组和未合并SA组,比较风险调整后早期(0-90天)和晚期(91-364天)结局及住院费用。

主要发现

  • SA在既往房颤的CABG患者中实施比例为17%。
  • SA组术前特征更有利:急诊就诊15% vs 22%,CABG前2周心力衰竭31% vs 36%,慢性肺病27% vs 33%,肾衰竭4% vs 7%(均P<0.05)。
  • 风险调整后手术死亡率和围术期卒中率两组相似。
  • 风险调整后90天内生存相似,但90天后SA组生存显著更好(HR=0.58;P=0.03)。
  • 1年时SA组风险调整后心血管植入式电子装置植入率更高(HR=1.20;P=0.01),CABG住院费用(HR=1.11;P<0.01)和至1年住院费用(HR=1.06;P=0.02)也更高。

临床怎么用

  • 对于既往房颤接受CABG的患者,合并SA不增加手术死亡和卒中风险,但需考虑费用和电子装置植入风险。
  • SA可能与90天后生存改善相关,临床决策应个体化权衡获益与费用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: While surgical ablation (SA) for persistent atrial fibrillation (AF) can reduce recurrence of AF, its impact on longitudinal survival and health-care costs remains controversial. This study defines the clinical outcomes and costs associated with SA in patients with prior AF undergoing coronary artery bypass grafting (CABG). METHODS: A total of 3745 Medicare beneficiaries with prior AF who underwent CABG in 2013 were divided into 2 groups: those with and those without concomitant SA. Risk-adjusted early (0-90 days) and late (91-364 days) postoperative outcomes and inpatient costs were compared. RESULTS: SA was performed in 17% of CABG patients with prior AF. Preoperative characteristics favoured patients with SA: emergent presentation (15% vs 22%), heart failure in the 2 weeks prior to CABG (31% vs 36%), chronic lung disease (27% vs 33%) and renal failure (4% vs 7%) (all P < 0.05). Risk-adjusted operative mortality and perioperative stroke rates were similar in the 2 groups. Risk-adjusted survival was similar through 90 days, but significantly better with SA after 90 days [hazard ratio (HR) = 0.58; P = 0.03]. At 1 year, the risk-adjusted incidence of cardiovascular implantable electronic device implantation was greater with SA (HR = 1.20; P = 0.01). Risk-adjusted costs for the CABG admission (HR = 1.11; P < 0.01) and inpatient care through 1 year (HR = 1.06; P = 0.02) were also greater with SA. CONCLUSIONS: In the US Medicare population, SA was performed in 17% of CABG-AF patients in 2013. Operative risks for mortality and stroke did not increase with SA but costs did. Patients receiving SA, however, had significantly better risk-adjusted late survival.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Rankin JS, Lerner DJ, Braid-Forbes MJ, et al. One-year mortality and costs associated with surgical ablation for atrial fibrillation concomitant to coronary artery bypass grafting. Eur J Cardiothorac Surg. 2017. PMID: 28472412. doi:10.1093/ejcts/ezx126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。